Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000947871-25-000540
Filing Date
2025-05-15
Accepted
2025-05-15 18:46:15
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7145
2 JOINT FILING AGREEMENT ss4831135_ex99a.htm EX-99.A 6263
  Complete submission text file 0000947871-25-000540.txt   15438
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SCHEDULE 13G

Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Subject) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-83932 | Film No.: 25956417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)